You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMaprotiline
Accession NumberDB00934  (APRD00747)
TypeSmall Molecule
GroupsApproved
DescriptionMaprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Structure
Thumb
Synonyms
Maprotilina
Maprotilinum
Maprotylina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ludiomil Tab 10mgTablet10 mgOralNovartis Pharmaceuticals Canada Inc1985-12-312003-07-29Canada
Ludiomil Tab 25mgTablet25 mgOralNovartis Pharmaceuticals Canada Inc1976-12-312001-07-30Canada
Ludiomil Tab 50mgTablet50 mgOralNovartis Pharmaceuticals Canada Inc1976-12-312001-07-30Canada
Ludiomil Tab 75mgTablet75 mgOralNovartis Pharmaceuticals Canada Inc1976-12-312000-08-02Canada
Novo-maprotiline - Tab 10mgTablet10 mgOralNovopharm Limited1995-12-312005-08-10Canada
PMS-maprotilineTablet75 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet25 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet50 mgOralPharmascience IncNot applicableNot applicableCanada
Teva-maprotilineTablet75 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Teva-maprotilineTablet50 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Teva-maprotilineTablet25 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maprotiline HydrochlorideTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Maprotiline HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Maprotiline HydrochlorideTablet, film coated75 mg/1OralMylan Pharmaceuticals Inc.1988-10-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DeprileptNot Available
LudiomilNot Available
PsymionNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Maprotiline Hydrochloride
Thumb
  • InChI Key: NZDMFGKECODQRY-UHFFFAOYSA-N
  • Monoisotopic Mass: 313.15972748
  • Average Mass: 313.864
DBSALT000482
Categories
UNII2U1W68TROF
CAS number10262-69-8
WeightAverage: 277.4033
Monoisotopic: 277.183049741
Chemical FormulaC20H23N
InChI KeyQSLMDECMDJKHMQ-UHFFFAOYSA-N
InChI
InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
IUPAC Name
methyl(3-{tetracyclo[6.6.2.0²,⁷.0⁹,¹⁴]hexadeca-2,4,6,9,11,13-hexaen-1-yl}propyl)amine
SMILES
CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21
Pharmacology
IndicationFor treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.
Structured Indications
PharmacodynamicsMaprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline reuptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.
Mechanism of actionMaprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain. In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction of the alpha-wave frequency and an increase in the alpha-wave amplitude. However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and hetero-receptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Maprotiline is also a moderate peripheral α1 adrenergic antagonist, which may explain the occasional orthostatic hypotension reported in association with its use. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H1 receptor, which explains its sedative actions.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Alpha-1 adrenergic receptorProtein groupno
antagonist
Humannot applicabledetails
5-hydroxytryptamine receptor 2AProteinunknown
binder
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinunknown
binder
HumanP28335 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
D(2) dopamine receptorProteinunknown
binder
HumanP14416 details
Alpha-2 adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
Related Articles
AbsorptionSlowly, but completely absorbed from the GI tract following oral administration.
Volume of distribution

Maprotiline and its metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle. Maprotiline is readily distributed into breast milk to similar concentrations as those in maternal blood.

Protein binding88%
Metabolism

Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives. It is slowly metabolized primarily to desmethylmaprotiline, a pharmacologically active metabolite. Desmethylmaprotiline may undergo further metabolism to maprotiline-N-oxide.

SubstrateEnzymesProduct
Maprotiline
demethylmaprotilineDetails
Route of eliminationApproximately 60% of a single orally administered dose is excreted in urine as conjugated metabolites within 21 days; 30% is eliminated in feces.
Half lifeAverage ~ 51 hours (range: 27-58 hours)
ClearanceNot Available
ToxicityLD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Maprotiline is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Maprotiline.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Maprotiline is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Maprotiline can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Maprotiline.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Maprotiline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Maprotiline.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Maprotiline.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Maprotiline.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Maprotiline.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Maprotiline.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Maprotiline.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Maprotiline.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Maprotiline.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Maprotiline.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Maprotiline.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Maprotiline.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Maprotiline.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Maprotiline.Approved, Investigational
AmiodaroneMaprotiline may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Maprotiline.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Maprotiline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Maprotiline.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Maprotiline.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Maprotiline.Experimental
AnagrelideMaprotiline may increase the QTc-prolonging activities of Anagrelide.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Maprotiline.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline.Approved, Investigational
Arsenic trioxideMaprotiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMaprotiline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Maprotiline.Approved
AsenapineMaprotiline may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Maprotiline.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Maprotiline.Approved
AtomoxetineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Maprotiline.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Maprotiline.Vet Approved
AzelastineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Azelastine.Approved
AzithromycinMaprotiline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Maprotiline.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Maprotiline.Illicit
BedaquilineMaprotiline may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Maprotiline.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Maprotiline.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Maprotiline.Approved, Vet Approved
BetaxololThe metabolism of Maprotiline can be decreased when combined with Betaxolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bifeprunox.Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Maprotiline.Approved
BortezomibThe metabolism of Maprotiline can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Maprotiline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Maprotiline.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Maprotiline.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Maprotiline.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Maprotiline.Approved, Investigational
BuprenorphineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Maprotiline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Maprotiline.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Maprotiline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Maprotiline.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Maprotiline.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Maprotiline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Maprotiline.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Maprotiline.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Maprotiline.Approved
CarbamazepineThe metabolism of Maprotiline can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Maprotiline.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Maprotiline.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Maprotiline.Approved
CariprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Maprotiline can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibMaprotiline may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Maprotiline.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Maprotiline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Maprotiline.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Maprotiline.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Maprotiline.Approved
ChloroquineMaprotiline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorphenamine.Approved
ChlorpromazineMaprotiline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Maprotiline.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline.Approved
CholecalciferolThe metabolism of Maprotiline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Maprotiline.Approved
CinacalcetThe metabolism of Maprotiline can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Maprotiline.Approved, Vet Approved
CiprofloxacinMaprotiline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMaprotiline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Maprotiline.Approved
CitalopramMaprotiline may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMaprotiline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Maprotiline can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Maprotiline.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Maprotiline.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Maprotiline.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Maprotiline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Maprotiline.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Maprotiline.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.Approved, Illicit
ClotrimazoleThe metabolism of Maprotiline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineMaprotiline may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Maprotiline can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Maprotiline.Approved
CocaineThe metabolism of Maprotiline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Maprotiline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Maprotiline.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Maprotiline.Approved
CrizotinibMaprotiline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Maprotiline.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Maprotiline.Approved
Cyproterone acetateThe serum concentration of Maprotiline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Maprotiline.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Maprotiline.Approved
DantroleneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Maprotiline.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Maprotiline.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.Investigational
DarifenacinThe metabolism of Maprotiline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Maprotiline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Maprotiline.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Maprotiline.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Maprotiline.Approved
DeferasiroxThe serum concentration of Maprotiline can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Maprotiline can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Maprotiline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Maprotiline.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Maprotiline.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Maprotiline.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Maprotiline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Maprotiline.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Maprotiline.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Maprotiline.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Maprotiline.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Maprotiline.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Maprotiline.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Maprotiline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Maprotiline.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Maprotiline.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Maprotiline.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Maprotiline can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Maprotiline.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Maprotiline.Approved
DisopyramideMaprotiline may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Maprotiline.Approved, Investigational
DofetilideMaprotiline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMaprotiline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMaprotiline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Maprotiline.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Maprotiline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Maprotiline.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Illicit
DronedaroneMaprotiline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Maprotiline.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Maprotiline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Maprotiline.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Maprotiline.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Maprotiline.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.Approved, Investigational
EliglustatMaprotiline may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Maprotiline.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Maprotiline.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Maprotiline.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Maprotiline.Approved, Investigational
ErythromycinMaprotiline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramMaprotiline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Maprotiline.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Maprotiline.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Maprotiline.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Maprotiline.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Maprotiline.Approved
EthanolMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Maprotiline.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Maprotiline.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Maprotiline.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Maprotiline.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Maprotiline.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Maprotiline.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Maprotiline.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Maprotiline.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Maprotiline.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Maprotiline.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Maprotiline.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Maprotiline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Maprotiline.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Maprotiline.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Maprotiline.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Maprotiline.Approved
FlecainideMaprotiline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Maprotiline.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Maprotiline.Approved, Illicit
FluoxetineMaprotiline may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMaprotiline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Maprotiline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Maprotiline.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Maprotiline.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Maprotiline.Approved
FluvoxamineThe metabolism of Maprotiline can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Maprotiline.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Maprotiline is combined with gabapentin enacarbil.Approved
Gadobenic acidMaprotiline may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Maprotiline.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Maprotiline.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Maprotiline.Approved
GemifloxacinMaprotiline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Maprotiline.Approved, Illicit
GoserelinMaprotiline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMaprotiline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Maprotiline.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Maprotiline.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Maprotiline.Approved, Illicit, Withdrawn
HaloperidolMaprotiline may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Maprotiline.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Maprotiline.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Maprotiline.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Hydracarbazine.Approved
HydrocodoneMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Maprotiline.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Maprotiline.Approved
IbutilideMaprotiline may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Maprotiline.Approved
IloperidoneMaprotiline may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Maprotiline.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Maprotiline.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Maprotiline.Approved
IndalpineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Maprotiline.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Maprotiline.Approved, Investigational
IproclozideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproniazid.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Maprotiline.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Maprotiline.Approved, Vet Approved
IsoniazidThe metabolism of Maprotiline can be decreased when combined with Isoniazid.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Maprotiline.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Maprotiline.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Maprotiline.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Maprotiline.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Maprotiline.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Maprotiline.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Maprotiline.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Maprotiline.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Maprotiline.Approved
LenvatinibMaprotiline may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideMaprotiline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Maprotiline.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Maprotiline.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levodopa.Approved
LevofloxacinMaprotiline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Maprotiline.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.Approved
LidocaineThe metabolism of Maprotiline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Maprotiline.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Maprotiline.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Maprotiline.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Maprotiline.Approved
LopinavirMaprotiline may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Maprotiline.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Maprotiline.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Maprotiline.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Maprotiline.Investigational
LumefantrineMaprotiline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Maprotiline.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Maprotiline.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Maprotiline.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Maprotiline.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Maprotiline.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Maprotiline.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Maprotiline.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Maprotiline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Maprotiline.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Maprotiline.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Maprotiline.Approved
MethotrimeprazineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Maprotiline.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.Approved
Methylene blueMaprotiline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Maprotiline.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Maprotiline.Approved, Investigational
MetyrosineMaprotiline may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Maprotiline can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Maprotiline.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Maprotiline.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Maprotiline.Approved
MirtazapineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Maprotiline.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Maprotiline.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Maprotiline.Approved, Investigational
MoxifloxacinMaprotiline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Maprotiline.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Maprotiline.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Maprotiline.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Maprotiline.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Naratriptan.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Maprotiline.Approved
NevirapineThe metabolism of Maprotiline can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nialamide.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Maprotiline.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Maprotiline.Approved
NilotinibMaprotiline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Maprotiline.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Maprotiline.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Maprotiline.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Maprotiline.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Maprotiline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Maprotiline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Octamoxin.Withdrawn
OfloxacinMaprotiline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Maprotiline.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Maprotiline.Approved
OndansetronMaprotiline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Maprotiline.Approved, Illicit
OrphenadrineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Maprotiline.Investigational
OsimertinibThe serum concentration of Maprotiline can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Maprotiline.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Maprotiline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Maprotiline.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Maprotiline.Approved, Vet Approved
PaliperidoneMaprotiline may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Maprotiline.Approved, Investigational
PanobinostatThe serum concentration of Maprotiline can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pargyline.Approved
ParoxetineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.Approved
Peginterferon alfa-2bThe serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineMaprotiline may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Maprotiline.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
PerazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perazine.Investigational
PerflutrenMaprotiline may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Maprotiline.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Maprotiline.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Maprotiline.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Maprotiline can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Maprotiline.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenoxypropazine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Maprotiline.Approved, Vet Approved
PimozideMaprotiline may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Maprotiline.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Maprotiline.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Maprotiline.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Maprotiline.Approved
PramipexoleMaprotiline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Maprotiline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Maprotiline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Maprotiline.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Maprotiline.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Maprotiline.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Maprotiline.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Maprotiline.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Maprotiline.Approved
PrimaquineMaprotiline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Maprotiline can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideMaprotiline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Maprotiline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Maprotiline.Approved, Vet Approved
PromazineMaprotiline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promethazine.Approved
PropafenoneMaprotiline may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Maprotiline.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Maprotiline.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Maprotiline.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Maprotiline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Maprotiline.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Maprotiline.Approved, Illicit
QuetiapineMaprotiline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineMaprotiline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMaprotiline may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Maprotiline.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Maprotiline.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Maprotiline.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Maprotiline.Approved
RifampicinThe metabolism of Maprotiline can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Maprotiline.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Maprotiline.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ritanserin.Investigational
RitonavirThe metabolism of Maprotiline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Maprotiline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rizatriptan.Approved
RolapitantThe metabolism of Maprotiline can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Maprotiline.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Maprotiline.Vet Approved
RopiniroleMaprotiline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline.Approved
RotigotineMaprotiline may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Maprotiline.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Maprotiline is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Maprotiline.Approved, Vet Approved
SaquinavirMaprotiline may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Maprotiline.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Maprotiline.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Maprotiline.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Maprotiline.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Maprotiline.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Maprotiline.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Maprotiline.Approved, Investigational
SotalolMaprotiline may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Maprotiline.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Maprotiline.Experimental
StiripentolThe metabolism of Maprotiline can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.Approved, Investigational
SulfisoxazoleMaprotiline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Maprotiline.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Maprotiline.Approved, Investigational
SuvorexantMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Maprotiline.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Maprotiline.Approved
TandospironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Maprotiline.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Maprotiline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Maprotiline.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Maprotiline.Approved
TelavancinMaprotiline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMaprotiline may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Maprotiline.Approved
TenofovirThe metabolism of Maprotiline can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Maprotiline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineMaprotiline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Maprotiline.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Maprotiline.Investigational
ThalidomideMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Maprotiline can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Maprotiline.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Maprotiline.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioproperazine.Approved
ThioridazineMaprotiline may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Maprotiline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline.Approved
TiaprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Maprotiline.Approved
TiclopidineThe metabolism of Maprotiline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Maprotiline.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Maprotiline.Approved
TipranavirThe metabolism of Maprotiline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Toloxatone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Maprotiline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Maprotiline.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Maprotiline.Approved, Investigational
ToremifeneMaprotiline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Maprotiline.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Maprotiline.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Maprotiline.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Maprotiline.Approved
TropisetronTropisetron may increase the serotonergic activities of Maprotiline.Investigational
Uc1010The risk or severity of adverse effects can be increased when Maprotiline is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Maprotiline.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Maprotiline.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Maprotiline.Approved, Investigational
VandetanibMaprotiline may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Maprotiline.Approved
VemurafenibThe serum concentration of Maprotiline can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Maprotiline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Maprotiline.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Maprotiline.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Maprotiline.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Maprotiline.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Maprotiline.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Maprotiline.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Maprotiline.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine.Withdrawn
ZiprasidoneMaprotiline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Maprotiline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Maprotiline.Approved, Investigational
ZolpidemMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Maprotiline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Maprotiline.Approved
ZuclopenthixolMaprotiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Limit caffeine intake.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA21
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (64.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9903
Caco-2 permeable+0.7214
P-glycoprotein substrateSubstrate0.7836
P-glycoprotein inhibitor IInhibitor0.7667
P-glycoprotein inhibitor IIInhibitor0.7206
Renal organic cation transporterInhibitor0.6502
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5216
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.855
Ames testNon AMES toxic0.7713
CarcinogenicityNon-carcinogens0.9204
BiodegradationNot ready biodegradable0.8913
Rat acute toxicity2.5307 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7016
hERG inhibition (predictor II)Inhibitor0.8652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • American therapeutics inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
Prices
Unit descriptionCostUnit
Novo-Maprotiline 75 mg Tablet1.54USD tablet
Maprotiline HCl 75 mg tablet1.25USD tablet
Novo-Maprotiline 50 mg Tablet1.13USD tablet
Maprotiline 75 mg tablet0.91USD tablet
Maprotiline HCl 50 mg tablet0.86USD tablet
Maprotiline 50 mg tablet0.79USD tablet
Maprotiline HCl 25 mg tablet0.73USD tablet
Maprotiline 25 mg tablet0.69USD tablet
Novo-Maprotiline 25 mg Tablet0.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point93 °CPhysProp
water solubilitySlightly solubleNot Available
logP5.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00015 mg/mLALOGPS
logP4.89ALOGPS
logP4.37ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.3 m3·mol-1ChemAxon
Polarizability33.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0f6x-9560000000-f263c228ecd4df5d7e73View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassAnthracenes
Sub ClassNot Available
Direct ParentAnthracenes
Alternative Parents
Substituents
  • Anthracene
  • Tetralin
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Saba W, Valette H, Schollhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M: [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007 Jan;61(1):17-23. [PubMed:17068778 ]
  2. Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K, Dohi T: Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res. 2003 Feb 21;964(1):83-90. [PubMed:12573515 ]
  3. Cloonan SM, Drozgowska A, Fayne D, Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 2010 Mar;51(3):523-39. doi: 10.3109/10428190903552112. [PubMed:20141432 ]
  4. Dronjak S, Spasojevic N, Gavrilovic L, Varagic V: Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats. Neuro Endocrinol Lett. 2007 Oct;28(5):614-20. [PubMed:17984940 ]
  5. Mochizucki D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S15-9. [PubMed:15378668 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628 ]
  2. Cavero I, Lefevre-Borg F, Roach AG: Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol. 1981 Sep;74(1):143-8. [PubMed:6115693 ]
  3. Kanba S, Richelson E: Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res. 1984 Jun 18;304(1):1-7. [PubMed:6146381 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650 ]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411 ]
Kind
Protein group
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848 ]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U: Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9. [PubMed:12071336 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
  2. Eap CB, Cuendet C, Baumann P: Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 1988 Feb;337(2):220-4. [PubMed:3368020 ]
  3. Lynn K, Braithwaite R, Dawling S, Rosser R: Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol. 1981 Jan;19(1):73-7. [PubMed:7461027 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23